Cited by 161Schizophrenia research and treatmentMental Health and PsychiatryDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large, long-term trial

Harvey, Philip D., Rabinowitz, Jonathan, Eerdekens, Marielle, Davidson, Michael·2005·American Journal of Psychiatry

Open this paper in CoChat — free account

Abstract

OBJECTIVE: Cognitive impairment is a major determinant of functional outcome in schizophrenia. Treatment of cognitive impairment at the time of the first episode may have the potential to change functional outcomes of the illness. This study examined changes associated with treatment with risperidone compared with haloperidol in aspects of cognitive functioning known to be associated with functional outcomes. The study was conducted in a large group of patients experiencing their first episode of schizophrenia. METHOD: Cognitive assessments were conducted in 533 patients experiencing their first episode of schizophrenia or a related psychosis who had been randomly assigned to receive low doses of risperidone or haloperidol. The cognitive assessments were repeated at several different follow-up intervals; 359 patients were reexamined at the 3-month follow-up. The assessments included examinations of verbal and visuospatial episodic memory, vigilance, executive functioning, processing speed, and verbal fluency. Patients' clinical symptoms were also rated with the Positive and Negative Syndrome Scale. RESULTS: Improvements from baseline were found in the risperidone-treated patients for episodic memory, verbal fluency, vigilance, executive functioning, and visuomotor speed. Haloperidol-treated patients also showed improvements from baseline in episodic memory, vigilance, and visuomotor speed but not in executive functioning or verbal fluency. Comparison of differential treatment effects on a composite measure of cognitive functioning found that risperidone was significantly more beneficial than haloperidol after 3 months of treatment. Changes in Positive and Negative Syndrome Scale scores were correlated overall with improvement in the haloperidol-treated patients but not in the risperidone-treated patients. CONCLUSIONS: Treatment with risperidone at the time of the first episode of schizophrenia is associated with wide-ranging improvements in cognitive functioning. Overall improvement is significantly greater with risperidone than with haloperidol. Further, cognitive improvement associated with treatment with risperidone was not influenced by changes in symptoms, but that relationship was significant in haloperidol-treated patients.

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.162.10.1888

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the ‘‘right stuff’’?
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999
Wisconsin Card Sorting Test Manual – Revised and Expanded
Heaton, R. K., Chelune, C., Talley, J., Kay, G., & Curtiss, G. (1981) · Medical Entomology and Zoology · Cited by 2,975
Predictors of Relapse Following Response From a First Episode of Schizophrenia or Schizoaffective Disorder
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Neuropsychological Function in Schizophrenia
Saykin, A. J. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810310036007 · Cited by 1,160
Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia
Saykin, A. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020048005 · Cited by 1,086
Neuropsychology of First-Episode Schizophrenia: Initial Characterization and Clinical Correlates
Bilder, R. M., Goldman, R. S., Robinson, D. G., Reiter, G., Bell, L., Bates, J. A., Pappadopulos, E. A., Willson, D. F., Alvir, J., Woerner, M. G., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.549 · Cited by 906
Cognitive Impairment in Schizophrenia Is the Core of the Disorder
Elvevag, B., & Goldberg, T. E. (2000) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v14.i1.10 · Cited by 835
Auditory Working Memory and Wisconsin Card Sorting Test Performance in Schizophrenia
Gold, J. M. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830140071013 · Cited by 823
One hundred years of schizophrenia: a meta-analysis of the outcome literature
Hegarty, J. D., Baldessarini, R. J., Tohen, M. F., WATERNAUX, C. M., & Oepen, G. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.10.1409 · Cited by 771

Show all 38 references

Sorted by citations

Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,096
Cognitive deficits and functional outcome in schizophrenia
Bowie, C. R., & Harvey, P. D. (2006) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2006.2.4.531 · Cited by 648
Self-citation
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 664
Cognitive Impairment in Schizophrenia
Keefe, R. S. E., & Harvey, P. D. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_2 · Cited by 528
Self-citation
Cognitive Improvement After Treatment With Second-Generation Antipsychotic Medications in First-Episode Schizophrenia
Goldberg, T. E., GOLDMAN, R. S., Burdick, K. E., Malhotra, A. K., Lencz, T., Patel, R. C., Woerner, M. G., Schooler, N. R., Kane, J. M., & Robinson, D. G. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1115 · Cited by 396
Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST)
Davidson, M., Galderisi, S., Weiser, M., Werbeloff, N., Fleischhacker, W., Keefe, R. S. E., Boter, H., Keet, I. P. M., Prelipceanu, D., RYBAKOWSKI, J. K., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08060806 · Cited by 322
Self-citation
Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia
Young, J. W., Powell, S. B., Risbrough, V. B., Marston, H. M., & Geyer, M. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.02.004 · Cited by 312
Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison
Keefe, R. S. E., Sweeney, J. A., Gu, H., Hamer, R. M., Perkins, D. O., McEvoy, J. P., & Lieberman, J. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1061 · Cited by 280
Effect of second-generation antipsychotics on cognition: current issues and future challenges
Hill, S. K., Bishop, J. R., Palumbo, D. R., & Sweeney, J. A. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.143 · Cited by 236
Research in people with psychosis risk syndrome: a review of the current evidence and future directions
Correll, C. U., Hauser, M., Auther, A. M., & Cornblatt, B. A. (2010) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2010.02235.x · Cited by 204
Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates
Emsley, R. A., Rabinowitz, J., & Medori, R. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.09.013 · Cited by 194
Self-citation
A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia
GOFF, D. C., Lamberti, J. S., Leon, A. C., Green, M. F., Miller, A. L., Patel, J. K., Manschreck, T. C., Freudenreich, O., & Johnson, S. A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301444 · Cited by 181
Prefrontal cortex executive processes affected by stress in health and disease
Girotti, M., Adler, S. M., Bulin, S. E., Fucich, E. A., Paredes, D., & Morilak, D. A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.07.004 · Cited by 176
Assessing cognitive function in clinical trials of schizophrenia
Barnett, J. H., Robbins, T. W., Leeson, V. C., Sahakian, B. J., Joyce, E. M., & Blackwell, A. D. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.01.012 · Cited by 178
The FDA-NIMH-MATRICS Guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
Buchanan, R. W., Keefe, R. S. E., Umbricht, D., Green, M. F., Laughren, T., & Marder, S. R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq038 · Cited by 154
A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects
Woodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.08.021 · Cited by 145
Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data
Sakurai, H., Bies, R. R., Stroup, T. S., Keefe, R. S. E., Rajji, T. K., Suzuki, T., Mamo, D. C., Pollock, B. G., Watanabe, K., Mimura, M., et al. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr189 · Cited by 148
Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?
Keefe, R. S. E., Buchanan, R. W., Marder, S. R., Schooler, N. R., Dugar, A., Zivkov, M., & Stewart, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr153 · Cited by 138
Disruption of Performance in the Five-Choice Serial Reaction Time Task Induced By Administration of N-Methyl-D-Aspartate Receptor Antagonists: Relevance to Cognitive Dysfunction in Schizophrenia
Amitai, N., & Markou, A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.03.004 · Cited by 136
The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta-analyses of randomized controlled trials
Baldez, D. P., Biazus, T. B., Rabelo‐da‐Ponte, F. D., Nogaro, G. P., Martins, D. S., Kunz, M., & Czepielewski, L. S. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.03.028 · Cited by 140
Molecular mechanisms of stress-induced prefrontal cortical impairment: Implications for mental illness
Hains, A. B., & Arnsten, A. F. T. (2008) · Learning & Memory · doi:10.1101/lm.921708 · Cited by 127
Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics
Rodefer, J. S., Nguyen, T. N., Karlsson, J.-J., & Arnt, J. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301654 · Cited by 126
The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment
Meltzer, H. Y., Horiguchi, M., & Massey, B. W. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2137-8 · Cited by 120
Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment
Weiner, I., & Arad, M. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.05.004 · Cited by 119
Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia”
Japanese Society of Neuropsychopharmacology (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12193 · Cited by 105
Cognitive Impairments and the Prevention of Homelessness: Research and Practice Review
Backer, T. E., & Howard, E. A. (2007) · The Journal of Primary Prevention · doi:10.1007/s10935-007-0100-1 · Cited by 82
The heterogeneity of antipsychotic response in the treatment of schizophrenia
Case, M., Stauffer, V. L., Ascher‐Svanum, H., Conley, R. R., Kapur, S., Kane, J. M., Kollack‐Walker, S., Jacob, J., & Kinon, B. J. (2010) · Psychological Medicine · doi:10.1017/s0033291710001893 · Cited by 85
Working memory as a predictor of negative symptoms and functional outcome in first episode psychosis
González–Ortega, I., Mozos, V. D. L., Echeburúa, E., Mezo, M., Besga, A., de Azúa, S. R., Arrillaga, A. G.-P., Gutiérrez, M., Zorrilla, E. P., & González-Pinto, A. M. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.08.025 · Cited by 85
5‐HT6 antagonists as potential treatment for cognitive dysfunction
Liu, K. G., & Robichaud, A. J. (2009) · Drug Development Research · doi:10.1002/ddr.20293 · Cited by 80
A Meta-Analysis of Neuropsychological Functioning in Patients with Early Onset Schizophrenia and Pediatric Bipolar Disorder
Nieto, R. G., & Castellanos, F. X. (2011) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2011.546049 · Cited by 80
Hippocampal and orbital inferior frontal gray matter volume abnormalities and cognitive deficit in treatment-naive, first-episode patients with schizophrenia
Guo, X., Li, J., Wang, J., Fan, X., Hu, M., Shen, Y., Chen, H., & Zhao, J. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2013.12.015 · Cited by 77
Selective anterior cingulate cortex deficit during conflict solution in schizophrenia: An event-related potential study
Neuhaus, A. H., Koehler, S., Opgen‐Rhein, C., Urbanek, C., Hahn, E. W., & Dettling, M. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.06.012 · Cited by 82
Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder
Houthoofd, S., Morrens, M., & Sabbe, B. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.09.014 · Cited by 76
Trajectories and Antecedents of Treatment Response Over Time in Early-Episode Psychosis
Levine, S. Z., & Rabinowitz, J. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn120 · Cited by 72
Self-citation
Antipsychotic Drugs for First-Episode Schizophrenia
Salimi, K., Jarskog, L. F., & Lieberman, J. A. (2009) · CNS Drugs · doi:10.2165/11314280-000000000-00000 · Cited by 73
The executive control of attention differentiates patients with schizophrenia, their first-degree relatives and healthy controls
Breton, F., Planté, A., Legauffre, C., Morel, N., Adès, J., Gorwood, P. A. P. M., Ramoz, N., & Dubertret, C. (2010) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2010.11.019 · Cited by 69
Premorbid functioning and treatment response in recent-onset schizophrenia
Rabinowitz, J., Harvey, P. D., Eerdekens, M., & Davidson, M. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.013276 · Cited by 70
Self-citation
Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?
Ballesteros, A., Sánchez-Torres, A. M., López-Ilundain, J. M., Cabrera, B., Lobo, A., González-Pinto, A. M., Díaz‐Caneja, C. M., Corripio, I., Vieta, E., de la Serna, E., et al. (2018) · Psychological Medicine · doi:10.1017/s0033291717003774 · Cited by 66
The Brattleboro Rat Displays a Natural Deficit in Social Discrimination That Is Restored by Clozapine and A Neurotensin Analog
Feifel, D., Mexal, S., Melendez, G., Liu, P. Y. T., Goldenberg, J. R., & Shilling, P. D. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.15 · Cited by 63
Pro-Cognitive and Antipsychotic Efficacy of the α7 Nicotinic Partial Agonist SSR180711 in Pharmacological and Neurodevelopmental Latent Inhibition Models of Schizophrenia
Barak, S., Arad, M., Levie, A. D., Black, M. D., Griebel, G., & Weiner, I. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.232 · Cited by 57
Effects of acute antipsychotic treatment on brain activation in first episode psychosis: An fMRI study
Fusar‐Poli, P., Broome, M. R., Matthíasson, P., Williams, S., Brammer, M. J., & McGuire, P. K. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.01.003 · Cited by 55
Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults
Brooks, J. O., & Hoblyn, J. C. (2007) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988707308803 · Cited by 58
Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders
Trampush, J. W., Lencz, T., DeRosse, P., John, M., Gallego, J. A., Petrides, G., Hassoun, Y., Zhang, J., Addington, J., Kellner, C. H., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv120 · Cited by 53
Neural correlates of cognitive impairment in schizophrenia
Ortiz‐Gil, J., Pomarol‐Clotet, E., Salvador, R. M., Canales-Rodríguez, E. J., Sarró, S., Gomar, J. J., Guerrero, A., Sans-Sansa, B., Capdevila, A., Junqué, C., et al. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.083600 · Cited by 51
Putative cognitive enhancers in preclinical models related to schizophrenia: The search for an elusive target
Barak, S., & Weiner, I. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.011 · Cited by 51
Recent advances in treating cognitive impairment in schizophrenia
Galletly, C. A. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1302-9 · Cited by 49
The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis
Faber, G., Smid, H. G. O. M., Gool, A. R. V., Wiersma, D., & van den Bosch, R. J. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2011.02.003 · Cited by 50
Neonatal 6-hydroxydopamine lesions of the frontal cortex in rats: Persisting effects on locomotor activity, learning and nicotine self-administration
Rezvani, A. H., Eddins, D. M., Slade, S. K., Hampton, D., Christopher, N. C., Petro, A. E., Horton, K., Johnson, M. L., & Levin, E. D. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.04.020 · Cited by 50
Neuroimaging studies of the early stages of psychosis: A critical review
Fusar‐Poli, P., Allen, P., & McGuire, P. K. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.03.008 · Cited by 45
MK-801-induced deficits in social recognition in rats
Deiana, S., Watanabe, A., Yamasaki, Y., Amada, N., Kikuchi, T., Stott, C. G., & Riedel, G. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000178 · Cited by 49
A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work/school functioning
Nuechterlein, K. H., Ventura, J., Subotnik, K. L., Gretchen‐Doorly, D., Turner, L. R., Casaus, L. R., Luo, J. S., Boucher, M. L., Hayata, J. N., Bell, M. D., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720003335 · Cited by 44
Treatment Response Trajectories and Their Antecedents in Recent-Onset Psychosis
Levine, S. Z., Rabinowitz, J., Case, M. G., & Ascher‐Svanum, H. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181e68e80 · Cited by 43
Self-citation
A Review of Second-Generation Antipsychotic Discontinuation in First-Episode Psychosis
Miller, B. J. (2008) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000336756.65308.83 · Cited by 42
Management of Patients Presenting with Acute Psychotic Episodes of Schizophrenia
Thomas, P., Alptekın, K., Gheorghe, M., Mauri, M., Olivares, J. M., & Riedel, M. J. (2009) · CNS Drugs · doi:10.2165/00023210-200923030-00002 · Cited by 45
Clinical experience with risperidone and memantine in the treatment of Huntington's disease.
Cankurtaran, E. Ş., Özalp, E., Soygür, H., & Cakir, A. (2006) · PubMed Central · Cited by 41
Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs
Barak, S., & Weiner, I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009176 · Cited by 39
Dementia praecox redux: A systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia
Rowe, A. R., Mercer, L., Casetti, V., Sendt, K.-V., Giaroli, G., Shergill, S. S., & Tracy, D. K. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114564096 · Cited by 41
Sex-Dependent Antipsychotic Capacity of 17β-Estradiol in the Latent Inhibition Model: A Typical Antipsychotic Drug in Both Sexes, Atypical Antipsychotic Drug in Males
Arad, M., & Weiner, I. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.89 · Cited by 37
Impact of DRD2/ANKK1 and COMT Polymorphisms on Attention and Cognitive Functions in Schizophrenia
Nkam, I., Ramoz, N., Breton, F., Mallet, J., Gorwood, P. A. P. M., & Dubertret, C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170147 · Cited by 34
Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia
Maat, A., Cahn, W., Gijsman, H. J., Hovens, J. E. J. M., Kahn, R. S., & Aleman, A. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.009 · Cited by 35
Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: A naturalistic 12-month follow-up study
Guo, X., Zhai, J., Wei, Q., Twamley, E. W., Jin, H., Fang, M., Hu, M., & Zhao, J. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.08.027 · Cited by 35
Determination of aripiprazole in rat plasma and brain using ultra‐performance liquid chromatography/electrospray ionization tandem mass spectrometry
Feng, L., Terry, A. V., & Bartlett, M. G. (2012) · Biomedical Chromatography · doi:10.1002/bmc.2698 · Cited by 34
Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered
Gaisler‐Salomon, I., Diamant, L., Rubin, C., & Weiner, I. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0960-3 · Cited by 35
Mouse pharmacological models of cognitive disruption relevant to schizophrenia
Young, J. W., Powell, S. B., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.06.013 · Cited by 33
Cognitive enhancers as a treatment for heroin relapse and addiction
Ma, B., Mei, D., Wang, F., Liu, Y., & Zhou, W. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.025 · Cited by 30
Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone
Ayesa‐Arriola, R., Rodríguez-Sánchez, J. M., Pérez‐Iglesias, R., Roiz‐Santiáñez, R., Martínez‐García, O., Sánchez‐Moreno, J., Tabarés‐Seisdedos, R., Vázquez‐Barquero, J. L., & Crespo‐Facorro, B. (2013) · Psychopharmacology · doi:10.1007/s00213-013-2994-z · Cited by 31
Cognitive performance during the first year of treatment in first-episode schizophrenia: a case–control study
Olivier, M. R., Killian, S., Chiliza, B., Asmal, L., Schoeman, R., Oosthuizen, P., Kidd, M., & Emsley, R. A. (2015) · Psychological Medicine · doi:10.1017/s0033291715000860 · Cited by 31
Pharmacological Approaches to the Management of Cognitive Dysfunction in Schizophrenia
Harvey, P. D., & McClure, M. M. (2006) · Drugs · doi:10.2165/00003495-200666110-00004 · Cited by 31
Self-citation
Risperidone versus haloperidol for facial affect recognition in schizophrenia: Findings from a randomised study
Fakra, É., Salgado‐Pineda, P., Besnier, N., Azorin, J., & Blin, O. J. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701432536 · Cited by 30
Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients
Lee, S.-M., Chou, Y.-H., Li, M., Wan, F.-J., & Yen, M. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.03.016 · Cited by 30
Oculomotor and Neuropsychological Effects of Antipsychotic Treatment for Schizophrenia
Hill, S. K., Reilly, J. L., Harris, M. S. H., Khine, T. T., & Sweeney, J. A. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm112 · Cited by 30
Risperidone and Cognitive Function in Children With Disruptive Behavior Disorders
Pandina, G., Bilder, R. M., Harvey, P. D., Keefe, R. S. E., Aman, M. G., & Gharabawi, G. M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.036 · Cited by 28
Self-citation
Detection of the Moderately Beneficial Cognitive Effects of Low-Dose Treatment with Haloperidol or Clozapine in an Animal Model of the Attentional Impairments of Schizophrenia
Martínez, V., & Sarter, M. F. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301661 · Cited by 29
Neuroprotective agents in schizophrenia and affective disorders
Krebs, M., Leopold, K., Hinzpeter, A., & Schaefer, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.7.837 · Cited by 27
Effects of Risperidone on Procedural Learning in Antipsychotic-Naive First-Episode Schizophrenia
Harris, M. S. H., Wiseman, C. L., Reilly, J. L., Keshavan, M. S., & Sweeney, J. A. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.79 · Cited by 27
The Effect of Long-Acting Risperidone on Working Memory in Schizophrenia
Surguladze, S. A., Chu, E. M.-Y., Evans, A., Anilkumar, A. P., Patel, M. X., Timehin, C., & David, A. S. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815a256c · Cited by 25
Antipsychotic effects on cognition in schizophrenia: A meta-analysis of randomised controlled trials
Guilera, G., Pino, Ó., Gómez‐Benito, J., & Rojo, E. (2009) · The European Journal of Psychiatry · doi:10.4321/s0213-61632009000200002 · Cited by 25
Implementation considerations for multisite clinical trials with cognitive neuroscience tasks
Keefe, R. S. E., & Harvey, P. D. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn042 · Cited by 24
Self-citation
Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trial
Allott, K., Yuen, H. P., Baldwin, L., O'Donoghue, B. N., Fornito, A., Chopra, S., Nelson, B., Graham, J. R., Kerr, M., Proffitt, T., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02501-7 · Cited by 24
Antipsychotic agents: efficacy and safety in schizophrenia
de Sena, E. P., Araújo, de Oliveira, I., & Juruena, M. F. (2012) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s37429 · Cited by 26
Cognitive Efficacy of Quetiapine and Olanzapine in Early-Onset First-Episode Psychosis
Robles, O., Zabala, A., Bombín, I., Parellada, M., Moreno, D. M., Ruíz-Sancho, A., & Arango, C. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp062 · Cited by 24
Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacist–physician collaboration in the outpatient department
Sathienluckana, T., Unaharassamee, W., Suthisisang, C. C., Suanchang, O., & Suansanae, T. (2018) · Integrated Pharmacy Research and Practice · doi:10.2147/iprp.s176653 · Cited by 23
Nitric oxide synthase inhibition attenuates phencyclidine-induced disruption of cognitive flexibility
Wass, C., Svensson, L., Fejgin, K., Pålsson, E., Archer, T., Engel, J. A., & Klamer, D. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.01.011 · Cited by 22
Stability of medication in early psychosis: a comparison between second‐generation and low‐dose first‐generation antipsychotics
Opjordsmoen, S., Melle, I. S., Friis, S., Haahr, U., Johannessen, J. O., Larsen, T. K., Rund, B. R., Simonsen, E. H., Vaglum, P., & McGlashan, T. H. (2009) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2008.00103.x · Cited by 22
A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia
Wang, C., Li, Y., Yang, J., Su, L., Geng, Y., Li, H., Wang, J.-K., & Mu, J. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2012.12.021 · Cited by 22
Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia
van Veelen, N. M. J., Grootens, K. P., Peuskens, J., Sabbe, B., Salden, M. E., Verkes, R. J., Kahn, R. S., & Sitskoorn, M. M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.04.011 · Cited by 21
Predictive value of premorbid IQ, negative symptoms, and age for cognitive and social functions in Japanese patients with schizophrenia: A study using the Japanese version of the Brief Assessment of Cognition in Schizophrenia
Akiyama, K., Saitô, S., Saito, A., Ozeki, Y., Watanabe, T., Fujii, K., Honda, G., & Shimoda, K. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.10.070 · Cited by 20
The Course of Neurocognitive Changes in Acute Psychosis: Relation to Symptomatic Improvement
Anda, L. G., Brønnick, K., Johnsen, E., Kroken, R. A., Jørgensen, H. A., & Løberg, E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167390 · Cited by 21
The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia
Selva‐Vera, G., Balanzá‐Martínez, V., Salazar-Fraile, J., Sánchez‐Moreno, J., Martínez‐Arán, A., Correa‐Ghisays, P., Vieta, E., & Tabarés‐Seisdedos, R. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-47 · Cited by 20
The Association Between Cognitive Deficits and Clinical Characteristic in First-Episode Drug Naïve Patients With Schizophrenia
Peng, X., Hei, G., Yang, Y., Liu, C., Xiao, J., Long, Y., Huang, J., Zhao, J., & Wu, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.638773 · Cited by 19
Link between cognitive polygenic risk scores and clinical progression after a first-psychotic episode
Segura, À. G., Mezquida, G., Martínez-Pinteño, A., Gassó, P., Rodríguez, N., Moreno-Izco, L., Amoretti, S., Bioque, M., Lobo, A., González-Pinto, A. M., et al. (2022) · Psychological Medicine · doi:10.1017/s0033291722001544 · Cited by 19
Cognitive functioning in subjects with recent-onset psychosis from a low-middle-income environment: Multiple-domain deficits and longitudinal evaluation
Ayres, A. M., Scazufca, M., Menezes, P. R., Nakano, E. Y., Regina, A. C. B., Schaufelberger, M. S., Murray, R. M., McGuire, P. K., Rushe, T., & Busatto, G. F. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2009.11.001 · Cited by 18
Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model
Goetghebeur, P., Lerdrup, L., Sylvest, A., & Dias, R. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1990-9 · Cited by 18
Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms
Manuel Gurpegui, A., Álvarez, E., Bousoño, M., Ciudad, A., Gómez, J. C., & Olivares, J. M. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.04.003 · Cited by 17
Pharmacogenetic Approaches to Cognitive Enhancement in Schizophrenia
Burdick, K. E., Gopin, C. B., & Malhotra, A. K. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.581899 · Cited by 16
Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: A saccadic eye movement study
Babin, S. L., Hood, A. J., Wassef, A. A., Williams, N., Patel, S. S., & Sereno, A. B. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.06.004 · Cited by 19
Dissociable source-monitoring impairments in obsessive–compulsive disorder and schizophrenia
Lavallé, L., Bation, R., Dondé, C., Mondino, M., & Brunelin, J. (2020) · European Psychiatry · doi:10.1192/j.eurpsy.2020.48 · Cited by 18
Antipsychotic Medication-Induced Dysphoria: Its Meaning, Association with Typical vs. Atypical Medications and Impact on Adherence
Wu, H. E., & Okusaga, O. O. (2014) · Psychiatric Quarterly · doi:10.1007/s11126-014-9319-1 · Cited by 16
Dementia in schizophrenia
Radhakrishnan, R., Butler, R. N., & Head, L. (2012) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.110.008268 · Cited by 15
Blockade of serotonin 2A receptors prevents PCP-induced attentional performance deficit and CREB phosphorylation in the dorsal striatum of DBA/2 mice
Pozzi, L., Greco, B., Sacchetti, G., Leoni, G., Invernizzi, R. W., & Carli, M. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1738-6 · Cited by 15

Authors: Harvey, P. D., Rabinowitz, J., Eerdekens, M., & Davidson, M.
Affiliations: Bar-Ilan University (IL)
ORCID: Harvey, Philip D.
Rabinowitz, Jonathan
Davidson, Michael
Venue: American Journal of Psychiatry
Publisher: American Psychiatric Association Publishing
Published: 2005-10-01
Volume: 162
Issue: 10
Pages: 1888-1895
ISSN: 0002-953X (ISSN-L)
1535-7228
DOI: 10.1176/appi.ajp.162.10.1888
OpenAlex: W2166514927
Cited by: 161
References: 38
Citations by year: 2026: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 6 · 2020: 3 · 2019: 3 · 2018: 3 · 2017: 5 · 2016: 7 · 2015: 8 · 2014: 4 · 2013: 7 · 2012: 10
FWCI: 10.07
Type: journal article
Language: en
Open access: closed
Locations: American Journal of Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: cognitive impairment, first-episode psychosis, schizophrenia, risperidone, haloperidol, antipsychotic drugs, episodic memory, executive function, processing speed, verbal fluency, sustained attention, functional outcome
MeSH terms: Adult, Cognition Disorders, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Haloperidol, Humans, Male, Neuropsychological Tests, Psychiatric Status Rating Scales, Psychotic Disorders, Schizophrenia, Schizophrenic Psychology, Time Factors, Antipsychotic Agents, Treatment Outcome, Age of Onset, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large, long-term trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks